Event-free survival extended with long-term finerenone in heart failure

Long-term treatment with finerenone is estimated to extend event-free survival among people with heart failure with mildly reduced or preserved ejection fraction, according to a brief report published online Sept. 27 in JAMA Cardiology to coincide with the annual meeting of the Heart Failure Society of America, held virtually from Sept. 27 to 30.

Muthiah Vaduganathan, M.D., M.P.H., from Harvard Medical School in Boston, and colleagues estimated the long-term treatment effects of finerenone if treated during a patient’s lifetime in patients with heart failure with mildly reduced or preserved ejection fraction.

Analyses included data from the FINEARTS-HF trial, which was conducted in 37 countries across 653 sites. Participants, who were aged 40 years and older and had symptomatic heart failure and left ventricular ejection fraction of 40% or higher, were randomly assigned to finerenone (titrated to 20 or 40 mg) or placebo; 6,001 participants were included in the analysis.

The researchers found that for a 55-year-old participant, mean survival free from the primary composite outcome of time to cardiovascular death or worsening heart failure event was 13.6 and 10.5 years with finerenone and placebo, respectively, representing a gain of 3.1 years in event-free survival. For a 65-year-old participant, mean event-free survival was 11.0 and 8.9 years with finerenone and placebo, respectively, representing a gain of 2.0 years.

For every starting age between 50 and 80 years, the projected mean event-free survival was numerically greater with finerenone versus placebo. Even among individuals already treated with a sodium-glucose cotransporter 2 inhibitor, there were lifetime gains in event-free survival observed (3.1 years for a 65-year-old participant).

“The relative benefits reported during follow-up in the FINEARTS-HF trial can be interpreted together with these new projections of the expected absolute benefits with lifetime use of finerenone,” the authors write.

More information:
Muthiah Vaduganathan et al, Estimated Long-Term Benefits of Finerenone in Heart Failure, JAMA Cardiology (2024). DOI: 10.1001/jamacardio.2024.3782

Copyright © 2024 HealthDay. All rights reserved.

Citation:
Event-free survival extended with long-term finerenone in heart failure (2024, September 30)
retrieved 6 October 2024
from https://medicalxpress.com/news/2024-09-event-free-survival-term-finerenone.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

Earth orbits the ...

Explore More

Researchers map the brain’s self-healing abilities after stroke

A new study by researchers at the Department of Molecular Medicine at SDU sheds light on one of the most severe consequences of stroke: damage to the brain’s “cables” —

Research shows regular mobile phone is associated with increased risk of cardiovascular diseases

A new study in the Canadian Journal of Cardiology has found that regular mobile phone use was positively associated with incident cardiovascular diseases risk, especially in current smokers and individuals

High blood pressure while lying down linked to higher risk of heart health complications

People who had high blood pressure while lying flat on their backs had a higher risk of heart attack, stroke, heart failure or premature death, according to new research to